一个基于集体的3D残余网络用于阿尔茨海默病的分类
Xiaoli Yang1, Jiayi Zhou1, Chenchen Wang1
1School of Medical Technology and Engineering, Henan University of Science and Technology, Luoyang, China.
PloS one
|June 11, 2025
概括
这项研究引入了用于早期阿尔茨海默病 (AD) 诊断的深度学习合并方法. 该方法准确地将轻度认知障碍 (MCI) 与正常认知区分开来,并使用3D ResNet模型将早期与晚期MCI阶段区分开来.
科学领域:
- 神经学 神经学
- 人工智能的人工智能
- 医疗成像医学成像
背景情况:
- 阿尔茨海默病 (AD) 是导致痴呆的主要原因,轻度认知障碍 (MCI) 是关键的前体.
- 早期诊断MCI对于管理AD进展至关重要,但区分MCI与正常对照 (NC) 和区分早期MCI (EMCI) 与晚期MCI (LMCI) 存在诊断挑战,原因是微妙的神经成像变化.
研究的目的:
- 开发和评估一种新的深度学习方法,以准确诊断阿尔茨海默病.
- 通过神经成像数据,改善正常认知,MCI和MCI不同阶段 (EMCI和LMCI) 的差异化.
主要方法:
- 实施一个集体学习策略,整合多个3DResNet架构 (ResNet-18,ResNet-34,ResNet-50).
- 整合了卷积块注意模块 (CBAM),以提高模型对相关图像特征的关注度.
- 应用数据增强技术来解决数据局限性并提高模型的稳定性.
- 利用基于概率的加权整体方法,将来自单个3D CNN模型的预测结合起来.
主要成果:
- 实现了高诊断准确度:MCI与NC的94.87%,MCI与NC的92.31%. AD. 副总经理.
- 在区分MCI阶段方面表现出强的表现:95.49%的EMCI与LMCI.
- 在四个类别的分类中获得了极好的准确性:95.97%的NC与EMCI与LMCI与LMCI. AD. 副总经理.
结论:
- 提出的深度学习组合方法有效地诊断阿尔茨海默病及其前体阶段.
- 3D ResNet,CBAM和集体学习的整合为使用神经成像进行早期和准确的AD检测提供了一个有希望的方法.
更多相关视频
06:44Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
Published on: January 10, 2025
446
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
7.9K
相关概念视频
Alzheimer's Disease: Overview
454
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
454
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
